CO2023015911A2 - Vectores aavrh74 para la terapia génica de distrofias musculares. - Google Patents

Vectores aavrh74 para la terapia génica de distrofias musculares.

Info

Publication number
CO2023015911A2
CO2023015911A2 CONC2023/0015911A CO2023015911A CO2023015911A2 CO 2023015911 A2 CO2023015911 A2 CO 2023015911A2 CO 2023015911 A CO2023015911 A CO 2023015911A CO 2023015911 A2 CO2023015911 A2 CO 2023015911A2
Authority
CO
Colombia
Prior art keywords
gene therapy
muscular dystrophies
vectors
aavrh74
aavrh74 vectors
Prior art date
Application number
CONC2023/0015911A
Other languages
English (en)
Inventor
Arun Srivastava
Keyun Qing
Barry John Byrne
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of CO2023015911A2 publication Critical patent/CO2023015911A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

En este documento se proporcionan proteínas de la cápside de AAV modificadas, partículas, vectores de ácidos nucleicos y composiciones de los mismos, así como métodos para su uso.
CONC2023/0015911A 2021-04-23 2023-11-22 Vectores aavrh74 para la terapia génica de distrofias musculares. CO2023015911A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163179097P 2021-04-23 2021-04-23
US202263327410P 2022-04-05 2022-04-05
PCT/US2022/025916 WO2022226289A2 (en) 2021-04-23 2022-04-22 Aavrh74 vectors for gene therapy of muscular dystrophies

Publications (1)

Publication Number Publication Date
CO2023015911A2 true CO2023015911A2 (es) 2023-11-30

Family

ID=81648417

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0015911A CO2023015911A2 (es) 2021-04-23 2023-11-22 Vectores aavrh74 para la terapia génica de distrofias musculares.

Country Status (11)

Country Link
US (1) US20220347317A1 (es)
EP (1) EP4326857A2 (es)
JP (1) JP2024514962A (es)
KR (1) KR20240000542A (es)
AU (1) AU2022262407A1 (es)
BR (1) BR112023021495A2 (es)
CA (1) CA3217649A1 (es)
CO (1) CO2023015911A2 (es)
IL (1) IL307881A (es)
TW (1) TW202304954A (es)
WO (1) WO2022226289A2 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014025985A2 (pt) * 2012-04-18 2017-07-11 Childrens Hospital Philadelphia composição e métodos para transferência de gene altamente eficaz com o uso de variantes de capsídeo de aav
WO2016081927A2 (en) 2014-11-21 2016-05-26 University Of Florida Research Foundation, Inc. Genome-modified recombinant adeno-associated virus vectors

Also Published As

Publication number Publication date
WO2022226289A2 (en) 2022-10-27
BR112023021495A2 (pt) 2023-12-19
WO2022226289A3 (en) 2023-03-02
EP4326857A2 (en) 2024-02-28
CA3217649A1 (en) 2022-10-27
KR20240000542A (ko) 2024-01-02
US20220347317A1 (en) 2022-11-03
JP2024514962A (ja) 2024-04-03
AU2022262407A1 (en) 2023-10-26
AU2022262407A9 (en) 2023-11-09
TW202304954A (zh) 2023-02-01
IL307881A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
DOP2020000071A (es) Proteínas trispecificas y métodos de uso
CL2019002473A1 (es) Composiciones útiles para el tratamiento de atrofia muscular espinal.
PE20230767A1 (es) Redireccion del tropismo de las capsides de aav
CY1122654T1 (el) Ενωσεις για βελτιωμενη iiκη μεταγωγη
CO2018000134A2 (es) Factor ix modificado, y composiciones para la transferencia de genes a células, órganos y tejidos
BR112017017867A2 (pt) métodos e composições para tratamento de doenças oculares genéticas
MX2020004578A (es) Composiciones de casz y metodos de uso.
PE20181534A1 (es) Metodos escalables para producir un vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspension sin suero adecuado para uso clinico
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
EA202190512A1 (ru) Композиции и способы для производства векторов для генной терапии
BR112018011881A2 (pt) proteínas capsidiais modificadas para liberação aumentada de vetores de parvovírus
BR112018076394A2 (pt) genes de minidistrofina otimizados e cassetes de expressão e seu uso
BR112018011711A2 (pt) peptídeos de direcionamento para direcionar virus adeno-associados (aav)
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
CO2020013699A2 (es) Composiciones aav, métodos de fabricación y métodos de uso
BR112019002904A2 (pt) métodos e composições para transferência gênica direcionada
CO2022010342A2 (es) Composiciones y métodos para modular simultáneamente la expresión de genes
CL2021000994A1 (es) Distrofinas miniaturizadas y usos de las mismas
BR112022015601A2 (pt) Grandes vetores genéticos e dispensação e usos dos mesmos
BR112022003389A2 (pt) Proteína vp1 modificada isolada do capsídeo do sorotipo 5 do vírus adeno-associado (aav5), ácido nucleico isolado, capsídeo isolado, vetor baseado em raav5 e seu uso, composição farmacêutica, método para entrega de produto gênico
CO2022010227A2 (es) Proteínas de la cápside de virus adeno-asociados modificadas para la terapia génica ocular y métodos de uso de las mismas
CO2023015911A2 (es) Vectores aavrh74 para la terapia génica de distrofias musculares.
CL2018002900A1 (es) Construcciones de adn para la fabricación de polipéptidos bioterapéuticos para su uso en vacunas animales y agentes terapéuticos.
MX2020002809A (es) Genes rep de aav inducibles.
AR125416A1 (es) Vectores aavrh74 para terápia génica de distrofias musculares